EMN Falls Into Earnings as Analysts Inch Higher and Options Turn Bullish

Eastman Chemical dropped 2.2% on Tuesday to close at $65.34, underperforming a peer group that gained a median 2.7% on the week, with the November 5 earnings report now less than 24 hours away.

The most notable shift in positioning is in options, and it cuts against the bearish price action. The put/call ratio has compressed to 0.29, more than two standard deviations below its 20-day average of 0.44. That is near the most call-heavy reading of the past year, the 52-week low is 0.17. Through most of October the ratio held above 0.44, reflecting genuine caution ahead of the October 30 print. That print arrived with a 1.7% decline in the shares. The subsequent pivot toward calls is sharp and deliberate. Lending conditions add no pressure from the short side: availability of shares to borrow has expanded dramatically, reaching 8,122% of outstanding short interest, up nearly 90% on the week. With borrowing costs at 0.38%, their lowest level in a month, short sellers face no urgency to cover.

Short interest at 5.3% of the free float is real but not acute. The position has drifted roughly 14% higher over the past month, then edged back about 1.2% this week to around 6.1 million shares. FINRA's most recent fortnightly settlement figure put short shares at 6.25 million, implying days-to-cover of 4.2. That is a meaningful base, but with borrow this cheap and availability this wide, it represents a stable short rather than a pressured one. The short score of 42.2 has been drifting lower for two weeks, consistent with a position that is unwinding gently rather than building.

The Street's posture has become fractured in a way worth spelling out. After JP Morgan's downgrade to Neutral from Overweight on October 16 and a cluster of target cuts from UBS, RBC, and Citigroup in the weeks prior, the most recent moves since the October 30 print have actually turned constructive. RBC raised its target from $65 to $70 on November 4. Barclays lifted from $72 to $74 on November 2. Citigroup trimmed one point from its $76 target to $75 but kept its Buy rating. JP Morgan, the most bearish voice, held at $65 on November 2, leaving its target sitting exactly at where the stock closed Tuesday. The consensus mean is $75.13, which puts implied upside at around 15% from current levels. The earnings yield ranks in the 82nd percentile of the ORTEX universe, and forward EPS growth scores in the 75th, though near-term EPS momentum is weak, ranking in the 26th percentile on a 30-day basis.

Peer moves on Tuesday show how isolated EMN's decline was. WLK dropped 3.8% and PPG fell 2.9%, so the sector-wide pressure was real. But on the week, PPG gained nearly 7% and RPM added 7%, while EMN is down 1.2%. That relative underperformance keeps the stock at a discount to where the analysts who stayed constructive had been anchoring targets just weeks ago.

The alt data layer flags one fact worth noting: Eastman's Q2 2026 share repurchase was the smallest for any second quarter in 13 years, with zero shares bought back in the period as recorded by SEC EDGAR. That is a capital allocation signal the market will likely want an explanation for on the November 5 call.

The specific thing to watch on the November 5 print is whether management addresses the buyback pause and whether Additives and Functional Products pricing shows any sequential improvement, the two data points the remaining bulls are relying on to justify targets above $75.